Introduction
Several possibly disease-modifying treatments for Alzheimer's disease (AD) are currently being tested in phase 3 clinical trials. The identification of persons at risk of developing AD before symptom onset may thus soon become clinically relevant [1] .
Amyloid pathology is present several years before the clinical onset of AD [2] . The analysis of peptide amyloid  (A) 1-42 in cerebrospinal fluid (CSF) has good diagnostic properties for AD in the clinical and prodromal disease stages, as has the measurements of amyloid burden with positron emission tomography (PET) [3, 4] . These two measures are highly concordant [4] , and new AD criteria highlight their importance in directly reflecting amyloid pathology in AD [5] . However, neither CSF sampling through lumbar puncture nor amyloid PET investigation is feasible for screening to identify individuals at risk of developing AD in the general population. A blood test would be much practical in this context. Plasma A can be measured reliably using current assays, and given the firm relation between CSF A and AD pathology, it has been investigated as a possible biomarker for AD [6] [7] [8] [9] [10] .
Findings, however, are conflicting. Results of some studies have indicated that lower A 42 concentrations or A 42 :A 40 ratios are associated with a significantly increased risk of AD, whereas other studies have found the reverse relation or failed to identify any association [7] [8] [9] [10] . Funnel plots from a meta-analysis suggest the presence of publication bias toward studies showing a relationship between A 42 and AD [7] .
The aim of the present nested case-control study was to investigate the association between free plasma A and AD in a large sample of persons with preclinical AD and closely matched dementia-free controls, using plasma samples taken several years before AD diagnosis.
Methods

Participants
This nested case-control study is part of the Consortium on Health and Ageing: Network of Cohorts in Europe and the United States (CHANCES) project [11] . Participants were selected using a computerized procedure. Individuals diagnosed with AD at the University Hospital Memory Clinic, Umeå, Sweden, for whom stored EDTA plasma samples collected before clinical disease onset were available in the Medical Biobank of Umeå (The Northern Sweden Health and Disease Study Cohort [12] were identified. Samples were selected when suitable age-, sex-, cohort-and sampling date-matched dementia-free controls could be identified.
Specificera pre-analytics (är det EDTA plasma, hur togs proverna [på morgonen eller närsomhelst, fastande eller inte], hur centrifugerades och alikvoterades proverna?)
Confirmation of AD diagnoses
All AD cases had been examined and diagnosed at the University Hospital Memory Clinic in Umeå, Sweden. These diagnoses were the result of regular clinical investigations and were not related to participation in any study cohort. The diagnosis of AD was supported by typical symptoms of progressive cognitive failure; physical examination findings; results of cognitive screening tests, such as the Mini-Mental State Examination [13] ; results of standard blood tests; and findings of examination using at least one brain imaging technique (x-ray computed tomography, magnetic resonance tomography, The dementia-free status of matched controls was checked using Swedish diagnosis registries, and persons were excluded when the diagnosis of any dementia disorder was found. The Swedish Death Registry was used to confirm that all controls were alive on the date of AD diagnosis for corresponding cases.
Plasma analyses
Plasma A 40 and A 42 concentrations were measured using Luminex xMAP technology and the INNOBIA plasma A forms assays (Innogenetics, Ghent, Belgium), as described previously [16] . As the measurements were performed on neat EDTA plasma without any pre-treatment, we measured the pool of A for which epitopes were available to the antibodies (free A). Plasma A concentrations are presented in nanograms per liter. The measurements were performed in one round of experiments using one batch of reagents by board-certified laboratory technicians who were blinded to clinical data.
Statistical analysis
Conditional logistic regression was used to test whether differences in A variables between AD cases and dementia-free controls were associated with AD, in the full sample and in the following sub-groups: men and women, participants aged ≥60 and <60 years at the time of plasma sampling, and quartiles defined according to the interval between sampling and AD diagnosis. Multiple linear regression was used to investigate the effects of age and sex on plasma A concentrations. A linear mixed model was used to analyze changes in A level between first sample collection and AD diagnosis among cases. P < 0.05 was considered to be statistically significant. SPSS software (version 22.0 for Macintosh; IBM Corporation, Armonk, NY, USA) was used for statistical calculations.
Results
The selection procedure resulted in the identification of 339 pairs of AD cases and dementia- Plasma A measurements for preclinical AD cases and dementia-free controls are shown in Table 1 . Results of multiple logistic regressions analyses of the effects of age and sex on free A concentrations are presented in Table 2 . Among AD cases, greater age was associated significantly with higher concentrations of free plasma A 42 ; among controls, women had significantly higher concentrations of free A 40 than did men. Plasma concentrations of free A 40 and A 42 were correlated significantly among cases and controls (cases: 0.375, p < 0.001; controls: 0.492, p < 0.001).
Conditional logistic regression revealed no association between the difference in plasma concentrations of free A between cases and controls and AD (Table 1 ). In addition, subgroup analyses showed no such association according to sex and age (Table 3) .
No A variable was correlated significantly with the interval between plasma sampling and AD diagnosis (Table 4) . Analysis of quartiles defined according to this interval also showed no significant association with AD ( Table 5 ).
The analysis of changes in plasma A markers with linear mixed models included two or more samples from 150 AD cases. No significant change in markers in the years prior to diagnosis was detected (A 40 : +0.40 units/year, p = 0.317; A 42 : +0.11 units/year, p = 0.420).
Discussion
In this sample of persons with preclinical AD and closely matched dementia-free controls, plasma concentrations of free A were not associated with the risk of AD development.
Among those who developed AD, repeated plasma sampling samples in the years prior to diagnosis detected no changes in plasma concentrations of free A.
The strengths of the present study include the analysis of a large sample of preclinical AD cases, identified by cross-referencing of a population-based biobank with subsequent memory clinic records, the high clinical diagnostic quality of AD diagnoses, and the use of closely matched dementia-free controls. Plasma samples were taken an average 9.4 years before the AD diagnosis.
This study adds further evidence that free plasma A is not a reliable measure of AD risk, and thus that it should not be used as an AD biomarker. These findings are in line with previous reports of the low predictive value of plasma A [6, 9, 17] . Previous studies have shown a low degree of correlation between plasma and CSF concentrations of A [16] , and have demonstrated that plasma A does not reflect brain A deposition [18] . These results may explain the lack of association found in this and other studies.
One possible explanation for the weak association between plasma concentration of free A and AD is that the A peptides measured in plasma primarily represent production of A from extra-cerebral cell types. Platelets may be a significant source of plasma A [19] , and fibroblasts, for example, have been found to produce A upon cytomegalovirus infection [20] .
The current results are limited to the value of plasma concentrations of free A to predict the development of AD when measured in a preclinical phase. The results therefore do not exclude the possibility that certain fractions of blood or plasma A, or plasma A in combination with other markers, could have a predictive value. Furthermore, the results do not exclude the possibility that plasma A might have a diagnostic value in symptomatic phases of AD. These limitations must be taken into account when interpreting the results.
Conclusion
Plasma concentrations of free A could not predict the development of clinical AD, and A concentrations did not change in the years preceding AD diagnosis in this sample. These results indicate that free plasma A is not a useful biomarker for the identification of individuals at risk of developing clinical AD. 
